207 related articles for article (PubMed ID: 36753473)
21. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
22. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
Mazzonetto P; Milanezi F; D'Andrea M; Martins S; Monfredini PM; Dos Santos Silva J; Perrone E; Villela D; Schnabel B; Nakano V; Palmero EI; Braggio E; Cavalcanti TL; Guida G; Migliavacca MP; Scapulatempo-Neto C; Zalcberg I
Breast Cancer Res Treat; 2023 May; 199(1):127-136. PubMed ID: 36881271
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Stevens KN; Wang X; Fredericksen Z; Pankratz VS; Greene MH; Andrulis IL; Thomassen M; Caligo M; ; Nathanson KL; Jakubowska A; Osorio A; Hamann U; Godwin AK; Stoppa-Lyonnet D; Southey M; Buys SS; Singer CF; Hansen TV; Arason A; Offit K; Piedmonte M; Montagna M; Imyanitov E; Tihomirova L; Sucheston L; Beattie M; ; ; Neuhausen SL; ; Szabo CI; ; Simard J; Spurdle AB; Healey S; Chen X; Rebbeck TR; Easton DF; Chenevix-Trench G; Antoniou AC; Couch FJ
Breast Cancer Res Treat; 2012 Nov; 136(1):295-302. PubMed ID: 23011509
[TBL] [Abstract][Full Text] [Related]
27. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
Hakkaart C; Pearson JF; Marquart L; Dennis J; Wiggins GAR; Barnes DR; Robinson BA; Mace PD; Aittomäki K; Andrulis IL; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Belhadj S; Berger L; Blok MJ; Boonen SE; Borde J; Bradbury AR; Brunet J; Buys SS; Caligo MA; Campbell I; Chung WK; Claes KBM; ; ; Collonge-Rame MA; Cook J; Cosgrove C; Couch FJ; Daly MB; Dandiker S; Davidson R; de la Hoya M; de Putter R; Delnatte C; Dhawan M; Diez O; Ding YC; Domchek SM; Donaldson A; Eason J; Easton DF; Ehrencrona H; Engel C; Evans DG; Faust U; Feliubadaló L; Fostira F; Friedman E; Frone M; Frost D; Garber J; Gayther SA; Gehrig A; Gesta P; Godwin AK; Goldgar DE; Greene MH; Hahnen E; Hake CR; Hamann U; Hansen TVO; Hauke J; Hentschel J; Herold N; Honisch E; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James PA; Janavicius R; John EM; Joseph V; Karlan BY; Kemp Z; Kirk J; Konstantopoulou I; Koudijs M; Kwong A; Laitman Y; Lalloo F; Lasset C; Lautrup C; Lazaro C; Legrand C; Leslie G; Lesueur F; Mai PL; Manoukian S; Mari V; Martens JWM; McGuffog L; Mebirouk N; Meindl A; Miller A; Montagna M; Moserle L; Mouret-Fourme E; Musgrave H; Nambot S; Nathanson KL; Neuhausen SL; Nevanlinna H; Yie JNY; Nguyen-Dumont T; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Osorio A; Ott CE; Park SK; Parsons MT; Pedersen IS; Peixoto A; Perez-Segura P; Peterlongo P; Pocza T; Radice P; Ramser J; Rantala J; Rodriguez GC; Rønlund K; Rosenberg EH; Rossing M; Schmutzler RK; Shah PD; Sharif S; Sharma P; Side LE; Simard J; Singer CF; Snape K; Steinemann D; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Thull DL; Tischkowitz M; Toland AE; Trainer AH; Tripathi V; Tung N; van Engelen K; van Rensburg EJ; Vega A; Viel A; Walker L; Weitzel JN; Wevers MR; Chenevix-Trench G; Spurdle AB; Antoniou AC; Walker LC
Commun Biol; 2022 Oct; 5(1):1061. PubMed ID: 36203093
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
29. Identification of Recurrent Variants in
Jiang Y; Tian T; Yu C; Zhou W; Yang J; Wang Y; Wen Y; Chen J; Dai J; Jin G; Ma H; Shen H; Hu Z
Biomed Res Int; 2020; 2020():6739823. PubMed ID: 32879886
[No Abstract] [Full Text] [Related]
30. Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
Bernstein-Molho R; Galmor L; Laitman Y; Segev S; Friedman E
Cancer; 2021 Oct; 127(19):3599-3604. PubMed ID: 34157778
[TBL] [Abstract][Full Text] [Related]
31. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
[TBL] [Abstract][Full Text] [Related]
33. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
36. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I
Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072
[TBL] [Abstract][Full Text] [Related]
38. Double Heterozygosity for Rare Deleterious Variants in the
Madar L; Majoros V; Szűcs Z; Nagy O; Babicz T; Butz H; Patócs A; Balogh I; Koczok K
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895014
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
40. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Ricks-Santi L; McDonald JT; Gold B; Dean M; Thompson N; Abbas M; Wilson B; Kanaan Y; Naab TJ; Dunston G
Ethn Dis; 2017; 27(2):169-178. PubMed ID: 28439188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
